Chin, MKY; Hsia, Y; Goossens, H; Versporten, A; Bielicki, J; Sharland, M; Donà, D
(2020)
Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates.
Pediatr Infect Dis J, 39 (11).
pp. 1032-1034.
ISSN 1532-0987
https://doi.org/10.1097/INF.0000000000002847
SGUL Authors: Hsia, Yingfen
![[img]](https://openaccess.sgul.ac.uk/112308/6.hassmallThumbnailVersion/PIDJ-220-127_R2%20%283%29.pdf) ![](https://openaccess.sgul.ac.uk/112308/6.haspreviewThumbnailVersion/PIDJ-220-127_R2%20%283%29.pdf) Preview |
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (1MB)
| Preview
|
Abstract
Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.
Statistics
Item downloaded times since 26 Aug 2020.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |